VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Stewart on the Safety Profile of Carfilzomib in Multiple Myeloma Patients

A. Keith Stewart, MB ChB
Published: Tuesday, Jan 20, 2015



A. Keith Stewart, MB ChB, from the Mayo Clinic, discusses the safety profile of carfilzomib (Kyprolis) when used in combination with lenalidomide and dexamethasone for patients with relapsed multiple myeloma.

In other studies, carfilzomib has been linked to heart-related adverse events, including swelling, shortness of breath, and cardiac failure, according to Stewart.  However,  in the phase III ASPIRE trial, which studied carfilzomib in combination with lenalidomide and dexamethasone, it was shown that the addition of the carfilzomib did not significantly change the frequency or severity of adverse events. 

With carfilzomib, the number of adverse events was slightly higher, but there was only a modest increase in cardiac failure. Also, serious events did not increase significantly in the trial.



A. Keith Stewart, MB ChB, from the Mayo Clinic, discusses the safety profile of carfilzomib (Kyprolis) when used in combination with lenalidomide and dexamethasone for patients with relapsed multiple myeloma.

In other studies, carfilzomib has been linked to heart-related adverse events, including swelling, shortness of breath, and cardiac failure, according to Stewart.  However,  in the phase III ASPIRE trial, which studied carfilzomib in combination with lenalidomide and dexamethasone, it was shown that the addition of the carfilzomib did not significantly change the frequency or severity of adverse events. 

With carfilzomib, the number of adverse events was slightly higher, but there was only a modest increase in cardiac failure. Also, serious events did not increase significantly in the trial.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x